Entrada Therapeutics Inc (TRDA)
12.33
+0.14
(+1.15%)
USD |
NASDAQ |
Apr 18, 09:49
Entrada Therapeutics Shareholders Equity (Quarterly): 242.36M for Dec. 31, 2023
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 242.36M |
| September 30, 2023 | 246.66M |
| June 30, 2023 | 206.91M |
| March 31, 2023 | 229.61M |
| December 31, 2022 | 212.55M |
| September 30, 2022 | 233.22M |
| Date | Value |
|---|---|
| June 30, 2022 | 256.04M |
| March 31, 2022 | 277.39M |
| December 31, 2021 | 298.72M |
| September 30, 2021 | -72.59M |
| June 30, 2021 | -59.01M |
| December 31, 2020 | -41.49M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-72.59M
Minimum
Sep 2021
298.72M
Maximum
Dec 2021
169.20M
Average
231.42M
Median
Shareholders Equity (Quarterly) Benchmarks
| GlycoMimetics Inc | 38.41M |
| Lyell Immunopharma Inc | 654.95M |
| Candel Therapeutics Inc | 12.74M |
| Eliem Therapeutics Inc | 107.60M |
| NovaBay Pharmaceuticals Inc | 3.314M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 469.19M |
| Total Liabilities (Quarterly) | 226.83M |
| Current Ratio | 2.329 |